Log in

NASDAQ:GALTGalectin Therapeutics News Headlines

Add
Compare
Today's Range N/A
50-Day Range
$2.56
MA: $2.80
$3.11
52-Week Range N/A
Volume89,273 shs
Average Volume127,762 shs
Market Capitalization$155.69 million
P/E RatioN/A
Dividend YieldN/A
Beta2.42

Headlines

Galectin Therapeutics (NASDAQ GALT) News Headlines

Source:
DateHeadline
Galectin Therapeutics (NASDAQ:GALT) Shares Up 5.1%Galectin Therapeutics (NASDAQ:GALT) Shares Up 5.1%
americanbankingnews.com - August 5 at 9:17 PM
Is Galectin Therapeutics, Inc.'s (NASDAQ:GALT) Shareholder Ownership Skewed Towards Insiders?Is Galectin Therapeutics, Inc.'s (NASDAQ:GALT) Shareholder Ownership Skewed Towards Insiders?
finance.yahoo.com - August 3 at 1:21 PM
Galectin Therapeutics (NASDAQ:GALT) Stock Price Crosses Above 200-Day Moving Average of $2.52Galectin Therapeutics (NASDAQ:GALT) Stock Price Crosses Above 200-Day Moving Average of $2.52
www.americanbankingnews.com - July 29 at 3:56 AM
 Analysts Expect Galectin Therapeutics Inc. (NASDAQ:GALT) Will Post Earnings of -$0.09 Per Share Analysts Expect Galectin Therapeutics Inc. (NASDAQ:GALT) Will Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - July 21 at 4:38 PM
Intercepts Pain Is Galectins Gain: Clinical Outcomes In NASH Are CrucialIntercept's Pain Is Galectin's Gain: Clinical Outcomes In NASH Are Crucial
seekingalpha.com - July 7 at 9:35 AM
Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in CancerGalectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in Cancer
www.bloomberg.com - July 6 at 11:33 PM
Galectin launches new study of lead drug in NASHGalectin launches new study of lead drug in NASH
seekingalpha.com - June 30 at 1:18 PM
Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH CirrhosisGalectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis
finance.yahoo.com - June 30 at 1:18 PM
UPDATE -- Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH CirrhosisUPDATE -- Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis
finance.yahoo.com - June 30 at 1:18 PM
Galectin Therapeutics Shares March Higher, Can It Continue?Galectin Therapeutics' Shares March Higher, Can It Continue?
finance.yahoo.com - May 22 at 12:37 PM
GALT Galectin Therapeutics Inc. Common StockGALT Galectin Therapeutics Inc. Common Stock
www.nasdaq.com - May 20 at 11:43 PM
Galectin Therapeutics EPS beats by $0.03Galectin Therapeutics EPS beats by $0.03
seekingalpha.com - May 11 at 5:29 PM
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2020, and Provides Business UpdateGalectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2020, and Provides Business Update
finance.yahoo.com - May 11 at 5:29 PM
Companies Like Galectin Therapeutics (NASDAQ:GALT) Are In A Position To Invest In GrowthCompanies Like Galectin Therapeutics (NASDAQ:GALT) Are In A Position To Invest In Growth
finance.yahoo.com - May 4 at 5:00 PM
Galectin Therapeutics Submits Seamless Adaptively-Designed Phase 2b/3 NASH-RX Protocol in NASH CirrhosisGalectin Therapeutics Submits Seamless Adaptively-Designed Phase 2b/3 NASH-RX Protocol in NASH Cirrhosis
finance.yahoo.com - April 30 at 4:30 PM
Galectin Therapeutics Update on the Impact of COVID-19Galectin Therapeutics Update on the Impact of COVID-19
finance.yahoo.com - April 2 at 4:06 PM
Galectin Therapeutics Inc.Galectin Therapeutics Inc.
www.barrons.com - March 21 at 11:56 PM
Galectin Therapeutics EPS misses by $0.04Galectin Therapeutics EPS misses by $0.04
seekingalpha.com - March 16 at 9:47 AM
Galectin Therapeutics Reports Fiscal 2019 Financial Results and Provides Business UpdateGalectin Therapeutics Reports Fiscal 2019 Financial Results and Provides Business Update
finance.yahoo.com - March 16 at 9:47 AM
Galectin Therapeutics Inc. Common Stock (GALT) Institutional Holdings | NasdaqGalectin Therapeutics Inc. Common Stock (GALT) Institutional Holdings | Nasdaq
www.nasdaq.com - February 20 at 7:41 PM
Galectin Therapeutics Appoints Seasoned Biopharmaceutical Executive Pol F. Boudes, M.D. as Chief Medical OfficerGalectin Therapeutics Appoints Seasoned Biopharmaceutical Executive Pol F. Boudes, M.D. as Chief Medical Officer
finance.yahoo.com - February 20 at 9:40 AM
Galectin Therapeutics President and CEO Dr. Harold Shlevin to Present at the 3rd Global NASH Congress 2020Galectin Therapeutics' President and CEO Dr. Harold Shlevin to Present at the 3rd Global NASH Congress 2020
www.marketwatch.com - February 4 at 1:08 PM
Are Insiders Buying Galectin Therapeutics, Inc. (NASDAQ:GALT) Stock?Are Insiders Buying Galectin Therapeutics, Inc. (NASDAQ:GALT) Stock?
finance.yahoo.com - February 4 at 1:08 PM
Galectin Therapeutics’ President and CEO Dr. Harold Shlevin to Present at the 3rd Global NASH Congress 2020Galectin Therapeutics’ President and CEO Dr. Harold Shlevin to Present at the 3rd Global NASH Congress 2020
finance.yahoo.com - February 4 at 8:08 AM
Is Galectin Therapeutics Inc. (GALT) Going to Burn These Hedge Funds?Is Galectin Therapeutics Inc. (GALT) Going to Burn These Hedge Funds?
finance.yahoo.com - December 20 at 10:32 PM
Galectin Therapeutics: An Even Better Buy As It Hits 52-Week LowsGalectin Therapeutics: An Even Better Buy As It Hits 52-Week Lows
seekingalpha.com - December 12 at 5:50 PM
Galectin Therapeutics Phase 2 NASH Cirrhosis Clinical Trial Results on Belapectin (GR-MD-02) Published in GastroenterologyGalectin Therapeutics' Phase 2 NASH Cirrhosis Clinical Trial Results on Belapectin (GR-MD-02) Published in Gastroenterology
www.marketwatch.com - December 9 at 9:23 AM
Galectin Therapeutics’ Phase 2 NASH Cirrhosis Clinical Trial Results on Belapectin (GR-MD-02) Published in GastroenterologyGalectin Therapeutics’ Phase 2 NASH Cirrhosis Clinical Trial Results on Belapectin (GR-MD-02) Published in Gastroenterology
finance.yahoo.com - December 9 at 9:23 AM
Galectin Therapeutics Plans Adaptively Designed Phase 3 NASH-RX Clinical Trial in NASH CirrhosisGalectin Therapeutics Plans Adaptively Designed Phase 3 NASH-RX Clinical Trial in NASH Cirrhosis
finance.yahoo.com - December 5 at 2:43 PM
Galectin Therapeutics to Webcast Corporate Update on December 4, 2019, after Annual Meeting of StockholdersGalectin Therapeutics to Webcast Corporate Update on December 4, 2019, after Annual Meeting of Stockholders
finance.yahoo.com - November 26 at 8:39 AM
Galectin Therapeutics to Present at Anti-Fibrotic Drug Development (AFDD) SummitGalectin Therapeutics to Present at Anti-Fibrotic Drug Development (AFDD) Summit
www.benzinga.com - November 18 at 4:43 PM
Galectin Therapeutics EPS beats by $0.05Galectin Therapeutics EPS beats by $0.05
seekingalpha.com - November 12 at 8:55 AM
Galectin Therapeutics Reports Q3 2019 Financial ResultsGalectin Therapeutics Reports Q3 2019 Financial Results
finance.yahoo.com - November 12 at 8:55 AM
Galectin Therapeutics Reaches Agreement with Siemens Healthineers to Collaborate on NASH and Liver FibrosisGalectin Therapeutics Reaches Agreement with Siemens Healthineers to Collaborate on NASH and Liver Fibrosis
finance.yahoo.com - November 11 at 1:26 PM
Additional Ad Hoc Analysis of ELF Data from Galectin Therapeutics NASH-CX Phase 2 Clinical Trial to be Highlighted in Poster Presentation at the 2019 AASLD Liver MeetingAdditional Ad Hoc Analysis of ELF Data from Galectin Therapeutics NASH-CX Phase 2 Clinical Trial to be Highlighted in Poster Presentation at the 2019 AASLD Liver Meeting
finance.yahoo.com - November 5 at 8:37 AM
Were Not Worried About Galectin Therapeuticss (NASDAQ:GALT) Cash BurnWe're Not Worried About Galectin Therapeutics's (NASDAQ:GALT) Cash Burn
finance.yahoo.com - October 28 at 1:45 PM
We're Not Worried About Galectin Therapeutics's (NASDAQ:GALT) Cash BurnWe're Not Worried About Galectin Therapeutics's (NASDAQ:GALT) Cash Burn
finance.yahoo.com - October 28 at 1:45 PM
Galectin Therapeutics and Providence Cancer Institute nabs new patent in U.S.Galectin Therapeutics and Providence Cancer Institute nabs new patent in U.S.
seekingalpha.com - September 17 at 11:34 AM
Galectin Therapeutics and Providence Cancer Institute nab new patent in U.S.Galectin Therapeutics and Providence Cancer Institute nab new patent in U.S.
seekingalpha.com - September 17 at 11:34 AM
Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in Cancer ImmunotherapyGalectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in Cancer Immunotherapy
finance.yahoo.com - September 17 at 11:34 AM
Need To Know: Galectin Therapeutics, Inc. (NASDAQ:GALT) Insiders Have Been Buying SharesNeed To Know: Galectin Therapeutics, Inc. (NASDAQ:GALT) Insiders Have Been Buying Shares
finance.yahoo.com - August 27 at 10:27 PM
Galectin holders file to offer up to 1.7M sharesGalectin holders file to offer up to 1.7M shares
seekingalpha.com - August 10 at 5:38 AM
Galectin Therapeutics Submits Phase 3 NASH-RX Protocol in Nash Cirrhosis to FDAGalectin Therapeutics Submits Phase 3 NASH-RX Protocol in Nash Cirrhosis to FDA
finance.yahoo.com - August 5 at 8:53 AM
Galectin Therapeutics Raises $44.5 Million in Rights Offering and $2.5 Million from Warrant ExerciseGalectin Therapeutics Raises $44.5 Million in Rights Offering and $2.5 Million from Warrant Exercise
finance.yahoo.com - May 28 at 9:32 AM
What Type Of Shareholder Owns Galectin Therapeutics, Inc.'s (NASDAQ:GALT)?What Type Of Shareholder Owns Galectin Therapeutics, Inc.'s (NASDAQ:GALT)?
finance.yahoo.com - May 27 at 5:41 PM
Galectin sets lower price in rights offeringGalectin sets lower price in rights offering
seekingalpha.com - May 24 at 8:00 AM
Galectin Therapeutics Reports Alternate Price of Common Stock in Rights OfferingGalectin Therapeutics Reports Alternate Price of Common Stock in Rights Offering
finance.yahoo.com - May 23 at 7:43 PM
Galectin Therapeutics: Primed For Takeoff After The Rights Offering And New Clinical EvidenceGalectin Therapeutics: Primed For Takeoff After The Rights Offering And New Clinical Evidence
seekingalpha.com - May 15 at 5:49 PM
Galectin Therapeutics misses by $0.06Galectin Therapeutics misses by $0.06
seekingalpha.com - May 10 at 9:57 AM
Galectin Therapeutics Reports Q1 2019 Financial Results and Provides Business UpdateGalectin Therapeutics Reports Q1 2019 Financial Results and Provides Business Update
finance.yahoo.com - May 10 at 9:57 AM
This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.